Is Astrana Health (ASTH) overvalued or fairly valued?

MarketChacha shows Astrana Health's valuation in context — a trailing P/E of about 66.9, a forward P/E of about 12.3, a price-to-book of about 2.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Astrana Health's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.86×) from reported figures — education, not a rating.

What is Astrana Health's revenue?

Astrana Health reported revenue of $3.2B for FY2025, with net profit of $22.5M, per official filings.

What is the share price of Astrana Health (ASTH)?

Astrana Health last traded at $42.18 (-7.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Astrana Health

ASTH · NYSE · Healthcare · United States

$42.18-7.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:27 PM

Snapshot

TickerASTH

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees3,000

HeadquartersAlhambra, United States

Market cap$2.1B

P/E (TTM)66.9

P/B2.6

Volume302.76K

Websitewww.astranahealth.com

Filings tracked8

About Astrana Health

Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was founded in 1992 and is headquartered in Alhambra, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders22.9%
Institutions61.3%
Public & other15.8%

256 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.17.22%
Vanguard Portfolio Management LLC6.36%
325 Capital Llc5.14%
Vanguard Capital Management LLC4.78%
State Street Corporation4.61%
Dimensional Fund Advisors LP3.82%
Wellington Management Group, LLP3.75%
Geode Capital Management, LLC2.90%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Margin has compressed by about 3.7 points over the period — profitability is trending down.

Cash conversion1.86×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend4.4% → 0.7%

Margin has compressed by about 3.7 points over the period — profitability is trending down.

Return on equity2.9%

Latest ROE of 2.9% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 51% · PAT -39%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.0B · EPS 0.79

Est. earnings growth +17.0%

Next fiscal year

Rev $4.4B · EPS 3.42

Est. earnings growth +17.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$18.0852-wk range$51.60

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$2.1B

Day change

-7.2%

P/E (TTM)

66.9

Fwd P/E

12.3

P/B

2.6

Beta

0.89

Revenue (FY2025)

$3.2B

Net margin

0.7%

ROE

2.9%

Revenue CAGR (2y)

+51.5%

Profit CAGR (2y)

-39.1%

EPS (FY2025)

0.46

Net profit (FY2025)

$22.5M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ASTH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$3.2B	$22.5M	0.46	0.7%	2.9%
FY2024	$2.0B	$43.1M	0.90	2.1%	6.1%
FY2023	$1.4B	$60.7M	1.29	4.4%	9.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$965.1M	$14.4M	0.29	1.5%
2025Q3	$956.0M	$373,000	0.01	0.0%
2025Q2	$654.8M	$9.4M	0.19	1.4%
2025Q1	$620.4M	$6.7M	0.14	1.1%
2024Q3	$478.7M	$16.1M	0.33	3.4%
2024Q2	$486.3M	$19.2M	0.40	3.9%
2024Q1	$404.4M	$14.8M	0.31	3.7%
2023Q3	$348.2M	$22.1M	0.47	6.3%
2023Q2	$348.2M	$13.2M	0.28	3.8%
2023Q1	$337.2M	$13.1M	0.28	3.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure, Exhibits
SEC7/13/2026material
8-K — Executive/director change
SEC7/1/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC6/10/2026material
8-K — Reg FD disclosure, Exhibits
SEC5/12/2026material
8-K — Executive/director change
SEC5/12/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
8-K — Other events, Exhibits
SEC3/30/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.